Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cipla
McKesson
Baxter
Cantor Fitzgerald
Healthtrust

Generated: August 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,132,202

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,132,202
Title:Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
Abstract: Disclosed are methods and compositions to genetically modify substantially intact cells having cosmetic function to enhance the cosmetic appearance in mammals so as to enhance and/or maintain a biochemical and/or physiological process that has a positive effect on cosmetic appearance. The methods and compositions may provide cosmetic benefits such as reduced skin sagging, increased skin thickness, reduced wrinkles, increased skin thickness and collagen content, increased skin tone and elasticity, increased skin hydration, and improved skin texture and color.
Inventor(s): Tabor; Aaron T. (Winston-Salem, NC)
Assignee:
Application Number:13/383,612
Patent Claims:1. A method for the cosmetic genetic modification of skin cells having a cosmetic function in a subject comprising: topically administering a NTX-keratinocyte growth factor-1 plasmid to the skin cells of the subject, wherein the plasmid comprises an isolated polynucleotide encoding a keratinocyte growth factor-1 polypeptide, such that the keratinocyte growth factor-1 polypeptide is expressed in the skin cells having cosmetic function to enhance or maintain a biochemical or physiological process or both that has a positive effect on cosmetic appearance.

2. The method of claim 1, wherein the polynucleotide comprises at least one sequence selected from the group consisting of: (i) nucleotides 446 to 1030 of SEQ ID NO: 24; (ii) a sequence that is at least 90% identical to nucleotides 446 to 1030 of SEQ ID NO: 24; and (iii) a polynucleotide that encodes a protein having the sequence of SEQ ID NO: 23.

3. The method of claim 1, wherein the polynucleotide is maintained as a extrachromosomal plasmid.

4. The method of claim 1, wherein the polynucleotide is operably linked to a constitutive or an inducible promoter.

5. The method of claim 4, wherein the promoter is not ubiquitously expressed, but is expressed in the cells having cosmetic function.

6. The method of claim 1, wherein the polynucleotide is operably linked to an enhancer.

7. The method of claim 1, wherein the polynucleotide is operably linked to at least one of a functional poly A sequence, an intron, a cleavage sequence, a stop sequence, and a cap site.

8. The method of claim 1, wherein the polynucleotide is introduced as naked DNA into the cells having a cosmetic function.

9. The method of claim 1, wherein the polynucleotide is introduced into the cells having a cosmetic function via at least one of liposomes, nanoparticles, an emulsion, a thixogel, and an organoleptic gel.

10. The method of claim 1, wherein the polynucleotide is introduced into the cells having a cosmetic function via a water-in-oil emulsion or an oil-in-water emulsion.

11. The method of claim 1, wherein the polynucleotide is introduced into the cells having a cosmetic function via at least one of particle mediated transfer, voltage driven transfer, radio frequency ablation-mediated transfer, ultrasound, and microneedles.

12. The method of claim 1, wherein the plasmid comprising the isolated polynucleotide is topically administered in a composition comprising TE buffer, glycerin, and hydroxypropyl methylcellulose.

13. The method of claim 12, wherein the composition further comprises propylene glycol.

Summary for Patent:   Try a Free Trial

PCT Information
PCT FiledJuly 15, 2010PCT Application Number:PCT/US2010/042051
PCT Publication Date:January 20, 2011PCT Publication Number:WO2011/008904

Details for Patent 9,132,202

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Try a Free Trial 2029-07-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Try a Free Trial 2029-07-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Try a Free Trial 2029-07-17 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
US Department of Justice
Chubb
Argus Health
Harvard Business School
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.